On 10 November 2026, Beam Therapeutics announced that risto-cel, its one-time therapy for sickle cell disease, had met the main goal of its pivotal BEACON trial: patients went at least 12 consecutive months without a severe vaso-occlusive crisis, the sudden, agonising episodes in which sickled cells block blood flow. For a disease in which crises can mean hospital stays, organ damage and a shortened life, a year without one matters. But the announcement was only a topline summary, and several important questions remain unanswered.
What sickle cell disease does to the body
Sickle cell disease is an inherited blood disorder caused by a single point mutation, known as E6V, in the beta globin gene. That one-letter change makes the body produce faulty sickle haemoglobin, or HbS, which clumps into long, rigid fibres under low oxygen and bends red blood cells into a crescent shape.
Healthy red blood cells are soft, round discs that squeeze easily through the smallest blood vessels. Sickled cells are stiff and sticky: they jam up capillaries, cutting off oxygen to tissues, and they break apart far earlier than normal red blood cells, causing chronic anaemia. The result is sudden severe pain crises, infections, stroke, organ failure and early death. It is the most common inherited blood disorder in the United States, affecting an estimated 100,000 people there and about eight million people worldwide, according to Beam Therapeutics. Treatment has long been supportive — pain relief, transfusions and hydroxyurea — while the only established cure, a donor stem-cell transplant, reaches only a minority of patients.
What risto-cel is, and what base editing means
Risto-cel, whose full name is ristoglogene autogetemcel and which was previously known as BEAM-101, is an autologous cell therapy: it is made from the patient's own blood-forming stem cells, known as CD34+ cells. Doctors collect those cells, edit them in a laboratory, and return them after the bone marrow has been cleared with the chemotherapy drug busulfan.
The editing itself is what makes risto-cel different. It uses base editing, a newer form of gene editing that changes a single DNA letter — one base — without cutting both strands of the DNA double helix. Think of conventional CRISPR as scissors that snip DNA, and base editing as a pencil rewriting one letter. Because it avoids double-strand breaks, base editing is designed to be more precise and to carry a lower risk of the unintended rearrangements that can follow a DNA cut.
The edit targets the promoter regions of two genes, HBG1 and HBG2, which control the production of foetal haemoglobin, or HbF — the form of haemoglobin that dominates before birth. After birth, a protein called BCL11A switches HbF off. Risto-cel's edit stops BCL11A from binding to those promoters, without disrupting BCL11A itself, so the edited stem cells keep producing HbF into adulthood. HbF does not sickle, and it actively interferes with HbS clumping, so raising its levels should stop red blood cells from sickling. The idea copies a harmless natural condition, hereditary persistence of foetal haemoglobin, in which HbF stays on for life and sickle cell disease is far milder.
What the BEACON trial actually showed
BEACON is an open-label, single-arm, multicentre Phase 1/2 study: every participant received the therapy, and there was no placebo or comparison group. It enrolled patients aged 12 to 35 with severe disease who had suffered at least four severe crises in the two years before joining, per the earlier New England Journal of Medicine report.
At the data cutoff of 20 October 2026, a total of 49 people had been treated: 39 adults and 10 adolescents. Of those, 31 patients had completed the follow-up needed for the primary endpoint. That endpoint, known as VF12, is freedom from severe vaso-occlusive crises for at least 12 consecutive months, judged by independent adjudicators. Beam announced that BEACON achieved the VF12 endpoint, met all primary safety endpoints at a prespecified interim analysis, and met all secondary endpoints, including freedom from inpatient hospitalisation for severe crises for 12 months.
Earlier data from the same trial, published in the New England Journal of Medicine in May 2026, give a sense of what lies behind the headline: 31 treated patients had a mean foetal haemoglobin level above 60 percent of total haemoglobin, and no severe crises were seen after the early post-treatment period. On the strength of these results, Beam said it expects to submit a Biologics License Application — the formal request for approval — to the US Food and Drug Administration as early as the end of 2026. If accepted and approved, risto-cel could become the first base-edited therapy ever to reach patients. Beam will present earlier-cutoff data at the American Society of Hematology meeting in December 2026, with detailed pivotal results planned for a medical meeting in 2027.
How risto-cel differs from Casgevy and other gene therapies
Risto-cel is not the first gene therapy for sickle cell disease. In late 2023, regulators in the US and UK approved Casgevy, a CRISPR-based therapy that also works by raising foetal haemoglobin. Casgevy uses standard CRISPR-Cas9, which cuts both strands of DNA at the BCL11A enhancer, a switch that drives BCL11A production in red blood cells. Disabling that enhancer lowers BCL11A and reawakens foetal haemoglobin. It works, but the double-strand cut is DNA damage that cells must repair, and that repair can occasionally go wrong, producing larger deletions or rearrangements. Risto-cel's base editor, by contrast, changes one DNA letter in the HBG1 and HBG2 promoters without cutting the double helix at all, and it leaves BCL11A itself untouched. In principle, that should mean a cleaner, more predictable edit.
A second approved gene therapy, Lyfgenia, takes a different route entirely: it uses a lentivirus to insert a working copy of a modified beta-globin gene into the patient's stem cells, rather than editing the patient's own DNA. The type of edit shapes what regulators scrutinise — but it does not tell us which therapy works best. That needs outcome comparisons, and no head-to-head trial between risto-cel and Casgevy exists. For now, patients and doctors will be weighing two one-time therapies with the same broad aim, different editing machinery, and different amounts of long-term evidence behind them. Readers interested in how gene editing is being aimed at other diseases may also want to read our report on a CRISPR breakthrough targeting gene fusions behind one in five cancers.
What the results do NOT prove yet
The most important caveat is also the most obvious: this was a topline announcement, not a full scientific publication. Beam said the trial met its endpoints, but it did not say what proportion of the 31 patients with enough follow-up actually achieved 12 months without a severe crisis. A trial can meet its endpoint — a statistical threshold, not success in every patient — while leaving success rates undisclosed. Independent analysts noted the same gap within hours of the announcement. Until the detailed data appear, nobody outside the company can say how many patients benefited or how large the benefit was.
The detailed safety picture is likewise incomplete. Beam said all primary safety endpoints were met, but gave no numbers: no adverse-event rates and no update on the patient who died in the trial in 2024, attributed to a respiratory condition four months after treatment. The treatment process itself is intensive — stem-cell collection, strong chemotherapy to clear the bone marrow, and a transplant — and it carries real risks, including infertility, infection and, rarely, death, that are separate from the gene edit. BEACON is also single-arm and open-label, with no control group, so results rest on each patient's own history. And 12 months without a crisis is not a lifetime cure: whether the effect lasts for years is still unknown.
None of this diminishes the result; it puts it in its proper place. A prespecified interim analysis that meets its primary endpoint, with independent adjudication, is a genuine milestone — the strongest signal a trial can send before its full data are published. But a milestone is not a verdict — that comes when detailed results are presented in 2027 and regulators complete their review.
What it could mean for patients
If approved, risto-cel would add a second class of one-time gene therapy for sickle cell disease — and the first built on base editing. Choice matters: different therapies may suit different people, and competition can push down prices and waiting times. The disease affects about eight million people worldwide, most of them in sub-Saharan Africa, the Middle East and India — regions where the complex, hospital-intensive process of collecting, editing and transplanting stem cells is hardest to deliver. Approved gene therapies cost millions of dollars per patient, and coverage will shape who actually receives risto-cel.
For now, patience is the practical message for patients and families. Risto-cel remains investigational and is not approved anywhere. Nobody should change treatment based on a topline press release; anyone interested in gene therapy should discuss eligibility with their haematologist. The science of genetics is moving fast, as our report on a DNA test study of 525,000 people shows, and our explainer on the APOE4 gene and the brain's blood vessels is a reminder that single genes can shape health in unexpected ways.
The road ahead
The next year will be decisive. A Biologics License Application as early as the end of 2026 would make risto-cel the first base-editing therapy ever submitted to the FDA. The FDA has already granted orphan drug status and a regenerative medicine advanced therapy designation to speed review. But submission is only the start: the FDA will examine the full data, including detailed safety results and manufacturing information, and it can ask for more evidence or more time. Approval is never guaranteed, and the history of gene therapy includes promising early results that did not survive closer scrutiny.
Whatever the outcome, the BEACON results mark a turning point for base editing. A technology that was recently a laboratory curiosity has now produced positive pivotal data in people. If risto-cel crosses the finish line, it will open the door for base-edited treatments for other genetic diseases — and for the millions of people living with sickle cell disease, it may offer a future measured not in crises survived, but in crises that never happen.
Disclaimer: This article is general information only and is not medical advice. Sickle cell disease is a serious condition: please speak to your doctor or haematologist before considering any treatment, including clinical trials.
Sources
- Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease — GlobeNewswire, 10 November 2026
- Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease — New England Journal of Medicine, 2026 (PubMed)
- BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease — ClinicalTrials.gov, NCT05456880